Viatris (VTRS) Long-Term Deferred Tax (2019 - 2026)
Viatris' (VTRS) quarterly Long-Term Deferred Tax came in at $1.1 billion in Q1 2026, up 35.67% year-on-year from $817.6 million in Q1 2025, and up 4.52% quarter-over-quarter from $1.1 billion in Q4 2025.
Viatris (VTRS) Long-Term Deferred Tax (2019 - 2026) Analysis & Trends
Viatris' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- On a quarterly basis, Long-Term Deferred Tax rose 35.67% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 35.67% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 40.93% from the prior year.
- Long-Term Deferred Tax rose to $1.1 billion in Q1 2026 per VTRS's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $1.3 billion in Q1 2022 and bottomed at $653.2 million in Q1 2024.
- The 5-year median for Long-Term Deferred Tax is $930.4 million (2023), against an average of $933.7 million.
- Across the five-year window, Long-Term Deferred Tax slumped 43.07% in 2022 and surged 40.93% in 2025, its largest moves.
- Year by year, Long-Term Deferred Tax stood at $925.9 million in 2022, then retreated by 25.16% to $692.9 million in 2023, then gained by 8.67% to $753.0 million in 2024, then jumped by 40.93% to $1.1 billion in 2025, then gained by 4.52% to $1.1 billion in 2026.
- Per Business Quant, the three latest VTRS Long-Term Deferred Tax figures stand at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $999.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 999.00 Mn |
| Jun 30, 2025 | 924.30 Mn |
| Mar 31, 2025 | 817.60 Mn |
| Dec 31, 2024 | 753.00 Mn |
| Sep 30, 2024 | 763.10 Mn |
| Jun 30, 2024 | 685.30 Mn |
| Mar 31, 2024 | 653.20 Mn |
| Dec 31, 2023 | 692.90 Mn |
| Sep 30, 2023 | 930.40 Mn |
| Jun 30, 2023 | 966.00 Mn |
| Mar 31, 2023 | 959.10 Mn |
| Dec 31, 2022 | 925.90 Mn |
| Sep 30, 2022 | 1.10 Bn |
| Jun 30, 2022 | 1.24 Bn |
| Mar 31, 2022 | 1.29 Bn |
| Dec 31, 2021 | 1.33 Bn |
| Sep 30, 2021 | 1.45 Bn |
| Jun 30, 2021 | 2.18 Bn |